e-SPACE Cardio-Renal-Metabolic 2023
Published: 25 March 2023
58m 54sPart 1 | Session 5 Plenary session 3 – Weight management in CRM disease
1h 6m 3sPart 1 | Session 7 Plenary session 4 – Guidelines implementation for acutely ill patients
58m 41sPart 1 | Session 8 Plenary session 5 – Mineralocorticoids antagonists in CRM disease
59m 5sPart 1 | Session 10 Plenary session 6 – Diuretics: old drugs, new data, new approaches
59m 17sPart 2 | Session 5 Plenary session 9 – Managing “metals”
1h 2m 16sPart 2 | Session 7 Plenary session 10 – Management of diabetes with kidney disease
1h 3m 10sPart 2 | Session 8 Plenary session 11 – Managing frail and elderly patients
1h 1m 47sPart 2 | Session 9 Plenary session 12 – Managing end-stage disease: focus on QoL
58m 8sPart 1 | Session 1 Plenary session 1 – HFpEF Andrew JS Coats, Giuseppe Rosano, Eberhard Standl, María José Soler, Stefan Anker
51m 57sPart 1 | Session 2 Satellite symposium – SGLT2 inhibitors in cardio-renal-metabolic patients – the perfect fit? (Supported by an educational grant from the Boehringer Ingelheim & Lilly Alliance) Stefan Anker, Paola Fioretto, Michel Jadoul
e-SPACE Cardio-Renal-Metabolic 2023 was the third edition of the annual global online conference that explores how leading experts, in cardiology, nephrology, and diabetology, are treating the interrelated diseases.
Course leadership Prof Stefan Anker (Berlin, DE), Dr Javed Butler (Texas, US), Prof Antonio Ceriello (Milan, IT), Prof Tara I Chang (California, US), Prof Ian de Boer (Washington, US), Prof Peter Rossing (Copenhagen, DK) and Prof Shelley Zieroth (Winnipeg, CA) lead an interactive programme of plenary sessions, meet the expert, case discussions and satellite symposium sessions focusing on the patient journey.
For the first time, e-SPACE Cardio-Renal-Metabolic 2023 brought together TMA’s mandate for the delivery of continuing professional development to healthcare professionals to achieve concordance with appropriate treatment plans, alongside KDIGO's mission to improve the care and outcomes of patients with kidney disease worldwide through the development and implementation of global clinical practice guidelines, with Radcliffe Cardiology’s goal to deliver cardiovascular knowledge to best support cardiovascular communities transform theory into practice.
- Review the burden of diabetes, kidney disease and heart failure including morbidity, excess mortality, and reduced quality of life affecting individuals around the world
- Describe the complexity and interlink between the three conditions
- Discuss existing guidelines and best approaches for screening patients
- Review evidence-based management strategies for diabetes, cardiovascular disease, heart failure, kidney disease & obesity including SLGT2i, GLP-1RA, new non-steroidal mineralocorticoid receptor antagonists and other emerging therapies
- Foster cross-collaboration between other cardiorenal / metabolic specialists and primary care physicians and allied health care professionals in order to improve patients outcomes
- General Practitioners (GPs)
- HF Specialists
- Nurses, Pharmacists, and other Allied Healthcare Professionals
More from this programme
Andrew JS Coats
Professor of Cardiology and Scientific Director
Prof Coats is Editor-in-Chief of the Cardiac Failure Review journal. He has published over 20 patents, more than 750 full research papers and more than 120,000 career citations and has a personal H-index of 146. Andrew was elected to the Presidential Trio of the Heart Failure Association of the ESC in 2018 and will serve as its president from 2020-2022.
Prof Coats is the Immediate past-President of the Heart Failure Association and past-Professor of Cardiology at the University of Warwick, UK. He has also held posts as Head of Cardiology at Imperial College, London and Associate Medical Director and Director of Cardiology at the Royal Brompton and Harefield Hospitals, London. From 2012 to 2017 he was Director of the Monash-Warwick Alliance, and before that served as Deputy Vice-Chancellor and Dean of Medicine at the University of Sydney.
He is an…
Prof Hiddo Heerspink’s is a Clinical Pharmacologist at the Department of Clinical Pharmacy and Pharmacology at the University Medical Center Groningen, the Netherlands. he also serves as a Visiting Professor at the University of New South Wales in Sydney, Australia. Prof Heerspink's research interests include treatment strategies and therapeutic approaches for the treatment of renal and cardiovascular disease in patients with diabetes.
Head of Diabetes Department
Prof Antonio Ceriello is Head of Diabetes Department at IRCCS MultiMedica, Milan, IT.
He has chaired the International Diabetes Federation (IDF) committee for the development in 2008, and in the 2011 for the update of “Guideline for Management of Postmeal Glucose".
Prof Ceriello has been a Member of the Board for the development of the new “European Society of Cardiology (ESC) guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD".
He has published over 450 original papers.
Associate Professor of Cardiology
Dr Gianluigi Savarese is currently an Associate Professor of Cardiology and Heart Failure Specialist at the Karolinska Institute in Stockholm, Sweden.
Dr Savarese has served on the board for the European Society of Cardiology's Heart Failure Association since 2020, and has previously been a Nucleus member of a working group on Cardiovascular Pharmacotherapy for the ESC. He is a member of the Italian Society of Cardiology, and the Swedish Society of Cardiology.
Dr Savarese attended the University of Naples Federico II University for his degree in Surgery and Medicine between 2004 - 2010. He then went on to stay at the same institution until 2016 as he completed his Specialism in Cardiovascular Diseases. He then continued his postgraduate studies at the University of Zurich between 2015-2017, where he continued his studies into Heart Failure. Finally, Dr Savarese completed his PhD at the Karolinska Institutet in 2018.
Professor of Medicine and Head of the Division of Nephrology, University of Würzburg, Germany
Prof Christoph Wanner is Professor of Medicine and Head of the Division of Nephrology, University of Würzburg, Germany. He completed fellowships at the Universities of Singapore and Internal Medicine in Zürich, Switzerland, and a residency in Internal Medicine and Nephrology at the University of Freiburg. Prof Wanner's clinical research is dedicated to studying the progression of cardiovascular and kidney disease. He has lectured internationally, and is widely published in leading peer-reviewed journals.